Searched for
DRUGMAKER COMPETITION
Defence startups raid auto and fracking sectors for parts to speed weapons outputSoaring demand for rocket motors used to power missiles and other weapons has spurred new thinking about supply chains. Seeking big returns...- Global Markets: S.Korean shares log best quarter in nearly 30 years on chipmaker rallySouth Korean stocks celebrated their best quarter in almost three decades, driven by a phenomenal surge in chipmakers. The KOSPI index soar...
- India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- School assembly news headlines for June 16: Top national, international, business, sports update and thought of the dayIndia and Slovakia elevate ties to a comprehensive partnership. A rival tutor accuses Khan Sir of murder. Delhi census Phase 1 records over...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...
- Global Markets: European shares edge higher with banks in the lead; the Middle East in focusEuropean markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after ...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- India's GCC model shifts from cost to capability as AI, talent strains biteIndia's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...
- Global firms bring more work in-house at India hubs on AI boostThe shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...
- Global firms bring more work in-house at India hubs on AI boostGlobal firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...
- Global firms rethink GCC hiring in India as AI shifts skill demandGlobal firms in India are hiring cautiously. Artificial intelligence is changing job roles, making it harder to find talent with advanced t...
- Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityEli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiativeRegeneron will reduce prices for its drugs on Medicaid. A cholesterol drug, Praluent, will be available for USD 225 on Trump's discounted d...
- Cholesterol drugmakers brace for competitionThe makers of cholesterol drugs are promoting their products ahead of a major change that is expected to trigger more competition in the ma...
Load More
